Dr Lal PathLabs to Acquire 70% Stake in SN Genelab

Dr Lal PathLabs is in focus in Friday’s market session after its board approved the acquisition of a 70% stake in Gujarat-based SN Genelab for up to ₹168 crore. The transaction also includes a performance-linked earn-out of up to ₹31.5 crore. Following completion, SN Genelab will become a subsidiary of Dr Lal PathLabs, with the company expecting the deal to strengthen its presence in genomics and advanced diagnostic services. The acquisition is expected to be completed by November 30, 2026, subject to customary conditions. The development was announced on September 24 and is among the corporate developments being tracked by the market today. Disclaimer: The views expressed purely for educational and informational purposes and do not constitute financial advice or a recommendation to buy, sell, or hold any security